Liposomal vincristine for relapsed or refractory Ph-negative acute lymphoblastic leukemia: a review of literature.

ABSTRACT: Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies that arise from clonal proliferation of immature lymphoid cells in the bone marrow, peripheral blood and other organs. There are approximately 3000 new adult cases diagnosed every year in the United States with a 5-year overall survival ranging from 22% to 50%. Most adult patients with ALL who achieve a complete response will ultimately relapse and for this subset of patients the only hope of curative therapy is successful re-induction to achieve a complete response followed by allogeneic transplant. Conventional vincristine has been used in all phases of ALL therapy but its efficacy is limited by cumulative toxicity, typically neuropathic in nature. Historically, the dose of conventional vincristine ha

SUBMITTER: Pathak P 

PROVIDER: S-EPMC3891290 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature